Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates

23 Mar 2020 - Yahoo News
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the full year ended December 31, 2019, and provided business updates.
usx:stok

---

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference

24 Feb 2020 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 40th Annual Cowen Health ...
usx:stok

---

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

7 Jan 2020 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 38th Annual J.P. Morgan Healthcare ...
usx:stok

---

Stoke Therapeutics Added to NASDAQ Biotechnology Index

23 Dec 2019 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition ...
usx:stok

---

Hedge Funds Are Selling Stoke Therapeutics, Inc. (STOK)

19 Dec 2019 - Yahoo News
We can judge whether Stoke Therapeutics, Inc. (NASDAQ:STOK) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow ...
usx:stok

---

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

8 Dec 2019 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of ...
usx:stok

---

Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

7 Dec 2019 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed significant improvements in survival and reductions ...
usx:stok

---

Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

26 Nov 2019 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Piper Jaffray 31st Annual ...
usx:stok

---

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

25 Nov 2019 - Yahoo News
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it will present new preclinical data on STK-001, a potential new disease-modifying medicine ...
usx:stok

---

Can The Uptrend Continue for Stoke Therapeutics?

22 Nov 2019 - Yahoo News
As of late, it has definitely been a great time to be an investor Stoke Therapeutics.
usx:stok

---